Geographic Atrophy GA Market

ID: MRFR/HC/9297-HCR
120 Pages
Vikita Thakur
Last Updated: April 06, 2026
Geographic Atrophy (GA) Market Research Report Information By Age Group (Above 60 Years and Above 75 Years), By Diagnosis (Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), and Multifocal Electroretinography (MfERG)), By Therapeutic Agents Clinical Phase (Late-Stage (Phase III), Phase II, Phase I, and Pre-Clinical Stage & Discovery Candidates) and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Summary Table of Contents Segmentation Methodology Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Disease Stage (USD Billion)
      1. 4.1.1 Early Stage
      2. 4.1.2 Intermediate Stage
      3. 4.1.3 Advanced Stage
    2. 4.2 Healthcare, BY Treatment Type (USD Billion)
      1. 4.2.1 Pharmacological Treatment
      2. 4.2.2 Surgical Intervention
      3. 4.2.3 Supportive Care
    3. 4.3 Healthcare, BY Patient Demographics (USD Billion)
      1. 4.3.1 Age Group
      2. 4.3.2 Gender
      3. 4.3.3 Socioeconomic Status
    4. 4.4 Healthcare, BY Diagnosis Method (USD Billion)
      1. 4.4.1 Fundus Examination
      2. 4.4.2 Optical Coherence Tomography
      3. 4.4.3 Fluorescein Angiography
    5. 4.5 Healthcare, BY Healthcare Setting (USD Billion)
      1. 4.5.1 Hospital
      2. 4.5.2 Outpatient Clinic
      3. 4.5.3 Home Care
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Regeneron Pharmaceuticals (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bayer (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Alcon (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Pfizer (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Santen Pharmaceutical (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Bausch Health (CA)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 INDIA MARKET ANALYSIS BY DISEASE STAGE
    3. 6.3 INDIA MARKET ANALYSIS BY TREATMENT TYPE
    4. 6.4 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    5. 6.5 INDIA MARKET ANALYSIS BY DIAGNOSIS METHOD
    6. 6.6 INDIA MARKET ANALYSIS BY HEALTHCARE SETTING
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY DISEASE STAGE, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY DISEASE STAGE, 2024 TO 2035 (USD Billion)
    15. 6.15 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    17. 6.17 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
    19. 6.19 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion)
    21. 6.21 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Billion)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DISEASE STAGE, 2026-2035 (USD Billion)
      2. 7.2.2 BY TREATMENT TYPE, 2026-2035 (USD Billion)
      3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
      4. 7.2.4 BY DIAGNOSIS METHOD, 2026-2035 (USD Billion)
      5. 7.2.5 BY HEALTHCARE SETTING, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

India Geographic Atrophy GA Market Segmentation

Geographic Atrophy GA Market By Disease Stage (USD Billion, 2026-2035)

  • Early Stage
  • Intermediate Stage
  • Advanced Stage

Geographic Atrophy GA Market By Treatment Type (USD Billion, 2026-2035)

  • Pharmacological Treatment
  • Surgical Intervention
  • Supportive Care

Geographic Atrophy GA Market By Patient Demographics (USD Billion, 2026-2035)

  • Age Group
  • Gender
  • Socioeconomic Status

Geographic Atrophy GA Market By Diagnosis Method (USD Billion, 2026-2035)

  • Fundus Examination
  • Optical Coherence Tomography
  • Fluorescein Angiography

Geographic Atrophy GA Market By Geographic Atrophy GA Market Setting (USD Billion, 2026-2035)

  • Hospital
  • Outpatient Clinic
  • Home Care

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035